Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.48 |
| ▸ | NOS3 | P29474 | 4/20 | 0.48 |
| ▸ | CCR1 | P32246 | 3/20 | 0.39 |
| ▸ | CCR5 | P51681 | 3/20 | 0.39 |
| ▸ | CCR8 | P51685 | 3/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.31 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.31 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24734425 | 0.82 | NOS2 (0.35) | NOS2NOS3PDE3BPDE3A | |
| SCHEMBL9019314 | 0.82 | NOS2 (0.50) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL10714692 | 0.79 | NOS2 (0.46) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL2083503 | 0.79 | NOS2 (0.46) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL27476555 | 0.79 | NOS2 (0.52) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL12309822 | 0.79 | PDE3B (0.42) | NOS2NOS3PDE3BPDE3ANOS1 | |
| SCHEMBL11306368 | 0.79 | NOS2 (0.52) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL660759 | 0.79 | NOS2 (0.46) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL11843661 | 0.79 | NOS2 (0.61) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL27839140 | 0.79 | NOS2 (0.43) | NOS2NOS3CCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111285849-A | Compound for targeted degradation of ALK, c-Met and ROS1 proteins and preparation method thereof | 上海青东生物科技有限公司 | 2020-06-16 | — | — | CN | claimed |
| CN-106977449-A | A kind of process for catalytic synthesis of the ethylpyridine of 3,5 dimethyl 2 | 东南大学 | 2017-07-25 | — | — | CN | claimed |
| EP-2748601-A1 | METHOD OF EASILY IDENTIFYING LUBRICATING OILS, IDENTIFICATION KIT AND LUBRICATING OILS THAT CAN BE EASILY IDENTIFIED | Shell Internationale Research Maatschappij B.V. (NL) | 2014-07-02 | — | — | EP | claimed |
| WO-2013050544-A1 | METHOD OF EASILY IDENTIFYING LUBRICATING OILS, IDENTIFICATION KIT AND LUBRICATING OILS THAT CAN BE EASILY IDENTIFIED | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2013-04-11 | — | — | WO | claimed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230128713-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20210387982-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-12-16 | — | — | US | disclosed |
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2021-01-14 | — | — | US | disclosed |
| CN-111491730-A | Zeolite catalyst | 弗特鲁斯控股有限责任公司 | 2020-08-04 | — | — | CN | disclosed |
| WO-2002098853-A2 | INHIBITORS OF CELL PROLIFERATION, ANGIOGENESIS, FERTILITY, AND MUSCLE CONTRACTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-12-12 | — | — | WO | disclosed |
| US-5962662-A | Method for producing a flavorful and aromatic composition for use in smoking articles | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
| US-5081247-A | Reacting a 2-alkoxy-2,3-dihydro-4H-pyran or a glutaraldehyde with ammonia in the presence of a zeolite | BASF AKTIENGESELLSCHAFT (DE) | 1992-01-14 | — | — | US | disclosed |
| EP-0289924-A2 | Process for the preparation of pyridines | DEGUSSA AG (DE) | 1988-11-09 | — | — | EP | disclosed |
| US-4588815-A | Method for manufacturing pyridine and pyridine derivatives from alkynes and cyano compounds in the presence of complex cobalt or rhodium compounds with ligands containing boron | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 1986-05-13 | — | — | US | disclosed |
| EP-0064268-B1 | METHOD FOR MANUFACTURING PYRIDINE AND PYRIDINE DERIVATIVES FROM ALKYNES AND CYANO COMPOUNDS IN THE PRESENCE OF COMPLEX COBALT OR RHODIUM COMPOUNDS WITH LIGANDS CONTAINING BORON | Studiengesellschaft Kohle mbH (DE) | 1985-09-18 | — | — | EP | disclosed |
| EP-0064268-A1 | Method for manufacturing pyridine and pyridine derivatives from alkynes and cyano compounds in the presence of complex cobalt or rhodium compounds with ligands containing boron | Studiengesellschaft Kohle mbH (DE) | 1982-11-10 | — | — | EP | disclosed |
| US-4204066-A | Preparation of alkyl pyridines | UOP INC. (US) | 1980-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387982-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | LCK, SRC, CILK1 | NOS2 2977/4885NOS3 3079/4885CCR1 1762/4885 |
| US-20230128713-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | ORC3, LEF1, OCIAD1 | NOS2 2140/4885NOS3 2270/4885CCR1 3044/4885 |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | ABL1, PRKDC, PRKACA | NOS2 3445/4885NOS3 2759/4885CCR1 3032/4885 |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | MITF, PRKDC, PRKACA | NOS2 2920/4885NOS3 2524/4885CCR1 3200/4885 |
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | NOS2 4845/4885NOS3 4868/4885CCR1 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.